Meeting
2020 ASCO Virtual Scientific Program
A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma.
Authors
Xuan Wang
Peking University Cancer Hospital and Institute, Beijing, China
Xuan Wang , Lu Si , Lili Mao , Chuanliang Cui , Zhihong Chi , Xinan Sheng , Xue Bai , Li Zhou , BIN LIAN , Bixia Tang , Xieqiao Yan , Siming Li , Yan Kong , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT 03973151
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10047)
DOI
10.1200/JCO.2020.38.15_suppl.10047
Abstract #
10047
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
First Author: Manish R. Patel
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
First Author: Reinhard Dummer
Poster
2013 ASCO Annual Meeting
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
First Author: Joanna Mangana
Poster
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.
First Author: Julie Ann Means-Powell